News

This designation provides Antigenics with, among other benefits, 10 years of potential market exclusivity if the product is approved for marketing in the EU. This is the second

The company has initiated a search for a successor that will consider internal and external candidates. Dr Pickett will continue to head R&D until his successor is appointed.

Matrix’s version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates. Lopinavir/ritonavir tablets are the generic version of Abbott Laboratories’s

According to the company, this once-daily oral medication, available in 40mg and 80mg tablets, is the first new treatment option for hyperuricemia in patients with gout in more

Mr Marver currently serves as the company’s COO and succeeds the company’s current CEO, John Hinson, who is leaving the company for personal reasons, effective March 30, 2009.

Currently, The Female Health Company (FHC) is manufacturing its second-generation product, FC2, on four production lines in Malaysia. The company, in conjunction with its Indian partner, HLL Lifecare,

The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque

Dara Biosciences, a development-stage pharmaceutical company, has announced that the FDA has cleared the company’s investigational new drug application for DB959, allowing Dara to commence Phase I studies

Cell Genesys, a biotechnology company, has reported a net loss of $13.3m, or $0.15 per diluted share, for the fourth quarter of 2008, compared to a net loss